Investor@Recursion.com<\/a><\/u><\/p>\nForward-Looking Statements<\/strong> \nThis document contains information that includes or is based upon “forward-looking statements” within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, all statements that are not historical facts. Forward-looking statements may or may not include identifying words such as \u201cplan,\u201d \u201cwill,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cbelieve,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d and similar terms. These statements are subject to known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including but not limited to: challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at any stage prior to or after regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors; our ability to leverage and enhance our drug discovery platform; our ability to obtain financing for development activities and other corporate purposes; the success of our collaboration activities; our ability to obtain regulatory approval of, and ultimately commercialize, drug candidates; our ability to obtain, maintain, and enforce intellectual property protections; cyberattacks or other disruptions to our technology systems; our ability to attract, motivate, and retain key employees and manage our growth; inflation and other macroeconomic issues; and other risks and uncertainties such as those described under the heading \u201cRisk Factors\u201d in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K. All forward-looking statements are based on management\u2019s current estimates, projections, and assumptions, and Recursion undertakes no obligation to correct or update any such statements, whether as a result of new information, future developments, or otherwise, except to the extent required by applicable law.<\/p>\nA photo accompanying this announcement is available at\u00a0https:\/\/www.globenewswire.com\/ NewsRoom\/AttachmentNg\/ 21f011ab-bada-4c3e-a55f- d8eabecf35ad<\/a><\/p>\nGlobeNewswire Distribution ID 9090097<\/p>\n","protected":false},"excerpt":{"rendered":"
Dr. Khan, formerly the Chief Data Science Officer and Global Head of Strategy and Portfolio, Innovative Medicine R&D at Johnson & Johnson (J&J), will also join Recursion\u2019s Board of Directors Photo of Najat Khan, Ph.D. SALT LAKE CITY, April 16, 2024 (GLOBE NEWSWIRE) \u2014 Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space [\u2026]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[35],"tags":[10,19,12],"yoast_head":"\n
Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer - Times South Africa<\/title>\n \n \n \n \n \n \n \n \n \n \n \n \n \n\t \n\t \n\t \n